Optimizing Anthracycline Therapy for Node Positive Breast Cancer

Authors: Cardoso F.; Atalay G.; Piccart M.J.

Source: American Journal of Cancer, Volume 1, Number 4, 2002 , pp. 257-268(12)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

Anthracyclines are among the most active cytotoxic drugs against breast cancer and are currently considered to be the standard agents for the adjuvant treatment of patients with node positive breast cancer. Nevertheless, the benefits attained by the use of the more active anthracycline schedules must be balanced against increased short- and long-term toxicity, and treatment options must be individualized for each patient. The authors review the available data regarding anthracycline efficacy and toxicity in the early breast cancer setting, the controversial issues still pending, and the potential directions for future research.

Keywords: Anthracyclines, therapeutic use; Antineoplastics, therapeutic use; Breast cancer, treatment; Taxanes, therapeutic use

Language: English

Document Type: Leading article

Affiliations: 1: Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium *

Publication date: 2002-01-01